Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation For The Treatment Of Cholangiocarcinoma
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics' drug, certepetide, has been granted Orphan Drug Designation by the FDA for treating cholangiocarcinoma, a type of cancer. This designation can provide benefits like market exclusivity and tax credits, potentially boosting Lisata's prospects.
September 05, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lisata Therapeutics' drug, certepetide, has received FDA Orphan Drug Designation for cholangiocarcinoma, which could lead to benefits such as market exclusivity and tax credits, potentially boosting the company's market position.
The FDA Orphan Drug Designation is significant for Lisata as it can provide market exclusivity, tax credits, and other benefits, which are likely to positively impact the company's stock price. The designation is a key regulatory milestone that can enhance the company's market position and investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100